Allergan’s Ubrelvy (ubrogepant) Receives the US FDA’s Approval for Acute Treatment of Migraine with or without Aura in Adults

 Allergan’s Ubrelvy (ubrogepant) Receives the US FDA’s Approval for Acute Treatment of Migraine with or without Aura in Adults

Allergan’s Ubrelvy (ubrogepant) Receives the US FDA’s Approval for Acute Treatment of Migraine with or without Aura in Adults

Shots:

  • The US FDA’s approval is based on four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002), which demonstrated efficacy, safety and tolerability of Ubrelvy (50, 100mg) for the acute treatment of migraine with/-out aura in adults
  • The studies resulted in meeting its 1EPs i.e, elimination in migraine pain and the most bothersome symptom (nausea, hypersensitivity to light and sound), providing lasting relief up to 24 hrs.
  • Ubrelvy is the first orally administered CGRP receptor antagonist (gepant), act without constricting blood vessels with no potential to cause addiction. The therapy is expected to be available in Q1’20

Click here to­ read full press release/ article | Ref: Allergan | Image: Nove.firenze

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post